HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
wPTnTb0CFHLfL5N3